Abstract
Objective
To examine the expressions of osteopontin (OPN), \(\alpha v^{\beta _3 }\) and Pim-1 in non-small cell lung cancer (NSCLC), and investigate their potential pathogenic roles in the development of NSCLC.
Methods
Immunohistochemistry was used to examine the expressions of OPN, \(\alpha v^{\beta _3 }\) and Pim-1 in cohort (136 cases) of NSCLC samples and their adjacent normal lung tissue specimens. Statistical analysis was performed to evaluate the relationships among expressions of OPN, \(\alpha v^{\beta _3 }\) and Pim-1 and their associations with patients clinico-pathological parameters.
Results
The expressions of OPN and Pim-1 were predominantly observed in cytoplasm. The expression of \(\alpha v^{\beta _3 }\) was mostly detected in cytoplasm and/or membrane. In NSCLC samples, the positive rates of OPN, \(\alpha v^{\beta _3 }\) and Pim-1 expressions were 68.4% (93/136), 77.2% (105/136) and 57.4% (78/136), respectively. In normal lung tissues, in contrast, the positive rates of OPN, \(\alpha v^{\beta _3 }\) and Pim-1 were 24.0% (12/50), 26.0% (13/50) and 16.0% (8/50), respectively. There were significant differences of the positive expression rates of OPN, \(\alpha v^{\beta _3 }\) and Pim-1 between NSCLCs samples and normal lung tissues (P<0.01). In addition, the positive expression of OPN, \(\alpha v^{\beta _3 }\) and Pim-1 in NSCLCs samples was significantly associated with increased pathological grade, lymph node metastasis and advanced clinical stage (P<0.01), and they were independent of other clinicopathological parameters (P>0.05). Furthermore, a significantly positive correlation between the expression of OPN and \(\alpha v^{\beta _3 }\) (r=0.38, P<0.01), OPN and Pim-1 (r=0.37, P<0.01), or \(\alpha v^{\beta _3 }\) and Pim-1 (r=0.20, P<0.05) was evaluated in our NSCLC cohort.
Conclusion
OPN, \(\alpha v^{\beta _3 }\) and Pim-1 proteins are frequently overexpressed in NSCLC, and they may play important roles in the development and/or progression of NSCLC.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71–96.
MacrÌ A, Versaci A, Lupo G, et al. Role of osteopontin in breast cancer patients. Tumori 2009; 95:48–52.
Bao LH, Sakaguchi H, Fujimoto J, et al. Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers. J Biomed Sci 2007; 14:373–381.
Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002; 2:91–100.
Verbisck NV, Costa ET, Costa FF, et al. ADAM 23 negatively modulates alpha(v)beta(3) integrin activation during metastasis. Cancer Res 2009; 69:5546–5552.
Bachmann M, Kosan C, Xing PX, et al. The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C. Int J Biochem Cell Biol 2006; 38:430–443.
Rami-Porta R, Crowley JJ, Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 2009; 15:4–9.
Di Cristofano A, Pesce B, Cordon-Cardo C, et al. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998; 19:348–355.
Senger DR, Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 1979; 16:885–893.
Zhang J, Takahashi K, Takahashi F, et al. Differential osteopontin expression in lung cancer. Cancer Lett 2001; 171:215–222.
Hu Z, Lin D, Yuan J, et al. Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 2005; 11:4646–4652.
Rodrigues LR, Teixeira JA, Schmitt FL, et al. The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev 2007; 16:1087–1097.
Chetty C, Lakka SS, Bhoopathi P, et al. MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells. Int J Cancer 2010; 127:1081–1095.
Krishnan N, Pan H, Buckley DJ, et al. Prolactin-regulated pim-1 transcription: identification of critical promoter elements and Akt signaling. Endocrine 2003; 20:123–130.
Beer AJ, Niemeyer M, Carlsen J, et al. Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET. J Nucl Med 2008; 49:255–259.
Lössner D, Abou-Ajram C, Benge A, et al. Integrin alphavbeta3 upregulates integrin-linked kinase expression in human ovarian cancer cells via enhancement of ILK gene transcription. J Cell Physiol 2009; 220:367–375.
Hsu AR, Hou LC, Veeravagu A, et al. In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in an orthotopic glioblastoma model. Mol Imaging Biol 2006; 8:315–323.
Wang Z, Bhattacharya N, Weaver M, et al. Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J Vet Sci 2001; 2:167–179.
Guo S, Mao X, Chen J, et al. Overexpression of Pim-1 in bladder cancer. J Exp Clin Cancer Res 2010; 29:161.
Warnecke-Eberz U, Bollschweiler E, Drebber U, et al. Prognostic impact of protein overexpression of the proto-oncogene PIM-1 in gastric cancer. Anticancer Res 2009; 29:4451–4455.
Kim DS, Sung JS, Shin ES, et al. Association of single nucleotide polymorphisms in PIM-1 gene with the risk of Korean lung cancer. Cancer Res Treat 2008; 40:190–196.
Zhang Y, Wang Z, Magnuson NS. Pim-1 kinase-dependent phosphorylation of p21Cip1/WAF1 regulates its stability and cellular localization in H1299 cells. Mol Cancer Res 2007; 5:909–922.
He HC, Bi XC, Zheng ZW, et al. Real-time quantitative RT-PCR assessment of PIM-1 and hK2 mRNA expression in benign prostate hyperplasia and prostate cancer. Med Oncol 2009; 26:303–308.
Fong YC, Liu SC, Huang CY, et al. Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway. Lung Cancer 2009; 64:263–270.
Cui R, Takahashi F, Ohashi R, et al. Abrogation of the interaction between osteopontin and alphavbeta3 integrin reduces tumor growth of human lung cancer cells in mice. Lung Cancer 2007; 57:302–310.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jin, Y., Tong, Dy., Tang, Ly. et al. Expressions of osteopontin (OPN), ανβ3 and Pim-1 associated with poor prognosis in non-small cell lung cancer (NSCLC). Chin. J. Cancer Res. 24, 103–108 (2012). https://doi.org/10.1007/s11670-012-0103-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11670-012-0103-1